Lilly Asia Ventures has contributed to an $85m series B round for Gracell Biotechnologies, whose shareholders also include 6 Dimensions Capital.
China-based gene therapies developer Gracell Biotechnologies obtained $85m in series B funding yesterday from investors including Lilly Asia Ventures, a regional investment subsidiary of pharmaceutical firm Eli Lilly.
Singaporean state-owned investment firm Temasek led the round, which also featured Suzhou municipal government-backed investment firm Kington Capital and its US dollar-denominated fund King Star Capital, and investment firm Chengdu Miaoji.
Founded in 2017, Gracell is working on immune cell gene therapies for cancer. It has completed preclinical development of several Car-T…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
